Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Onconova initiates Phase 1/2a study of rigosertib plus nivolumab » 08:26
06/22/20
06/22
08:26
06/22/20
08:26
ONTX

Onconova

$0.60 /

+0.0255 (+4.45%)

Onconova Therapeutics…

Onconova Therapeutics announced an investigator-initiated Phase 1/2a trial of oral rigosertib plus nivolumab in advanced metastatic KRAS mutated lung adenocarcinoma has begun enrolling patients. The investigator-initiated trial is an open-label, dose-escalating Phase 1 study followed by a Phase 2a dose-expansion phase to study the combination of oral rigosertib and nivolumab in metastatic KRAS+ lung adenocarcinoma patients who have progressed on standard frontline treatment. The study will assess safety and efficacy.

ShowHide Related Items >><<
ONTX Onconova
$0.60 /

+0.0255 (+4.45%)

ONTX Onconova
$0.60 /

+0.0255 (+4.45%)

05/15/20 Maxim
Onconova upgraded to Buy from Hold at Maxim
05/15/20 Maxim
Onconova upgraded to Buy from Hold at Maxim
11/26/19 Maxim
Onconova downgraded to Hold from Buy at Maxim
07/25/19
Fly Intel: Top five analyst initiations
Hot Stocks
Onconova presents genomic data from HMA-failure patients » 08:05
06/12/20
06/12
08:05
06/12/20
08:05
ONTX

Onconova

$0.59 /

+0.1132 (+23.74%)

Onconova Therapeutics…

Onconova Therapeutics announced updated aggregated baseline genomic data from HMA-failure patients screened for the INSPIRE trial were presented in an e-poster at the virtual 25th Annual EHA Congress. The on-demand presentation will be available on the EHA website as of Friday, June 12 at 8:30 a.m. CEST, and will be accessible until October 15, 2020. Abstract #EP829. "Mutations in RAS Pathway Genes Correlate with Type of Failure to Azacitidine: Genomic Analysis at Randomization onto the Inspire Trial."As an exploratory endpoint, bone marrow samples were collected at baseline, months 2, 4 and 6, and every 6 months thereafter, as well as at the end of treatment, for mutational analysis. Genomic DNA was extracted and deep sequencing of 295 genes will be performed on these samples following analysis of the primary endpoint. In total, 55 different mutations were identified at baseline, with the median number of mutations per patient at 3.

ShowHide Related Items >><<
ONTX Onconova
$0.59 /

+0.1132 (+23.74%)

ONTX Onconova
$0.59 /

+0.1132 (+23.74%)

05/15/20 Maxim
Onconova upgraded to Buy from Hold at Maxim
05/15/20 Maxim
Onconova upgraded to Buy from Hold at Maxim
11/26/19 Maxim
Onconova downgraded to Hold from Buy at Maxim
07/25/19
Fly Intel: Top five analyst initiations
Over a month ago
Upgrade
Onconova upgraded to Buy from Hold at Maxim » 08:03
05/15/20
05/15
08:03
05/15/20
08:03
ONTX

Onconova

$0.36 /

+0.0054 (+1.52%)

Maxim analyst Jason…

Maxim analyst Jason McCarthy upgraded Onconova to Buy from Hold with a $1.25 price target. The analyst says the company's Q1 update sees sufficient cash runway to last into Q3 of 2021 and well past the pivotal P3 INSPIRE study readout. McCarthy adds that the removal of the financing overhang should make the potentially positive data transformative for the company, with strategic partners also likely to take note and provide the footing for the second intended phase 3 study with rigosertib thereafter.

ShowHide Related Items >><<
ONTX Onconova
$0.36 /

+0.0054 (+1.52%)

ONTX Onconova
$0.36 /

+0.0054 (+1.52%)

05/15/20 Maxim
Onconova upgraded to Buy from Hold at Maxim
11/26/19 Maxim
Onconova downgraded to Hold from Buy at Maxim
07/25/19
Fly Intel: Top five analyst initiations
07/25/19 Noble Capital
Onconova initiated with an Outperform at Noble Capital
Upgrade
Onconova upgraded to Buy from Hold at Maxim » 07:34
05/15/20
05/15
07:34
05/15/20
07:34
ONTX

Onconova

$0.36 /

+0.0054 (+1.52%)

Maxim analyst Jason…

Maxim analyst Jason McCarthy upgraded Onconova to Buy from Hold.

ShowHide Related Items >><<
ONTX Onconova
$0.36 /

+0.0054 (+1.52%)

ONTX Onconova
$0.36 /

+0.0054 (+1.52%)

11/26/19 Maxim
Onconova downgraded to Hold from Buy at Maxim
07/25/19
Fly Intel: Top five analyst initiations
07/25/19 Noble Capital
Onconova initiated with an Outperform at Noble Capital
Hot Stocks
Onconova to hold Annual Meeting virtually » 08:52
05/11/20
05/11
08:52
05/11/20
08:52
ONTX

Onconova

$0.33 /

+0.0075 (+2.35%)

Onconova Therapeutics…

Onconova Therapeutics announced that, as disclosed in the Company's Definitive Proxy Statement for the Company's 2020 Annual Meeting of Stockholders, due to the public health impact of the COVID-19 pandemic, the Company's Annual Meeting of Stockholders will be held in a virtual meeting webcast format, beginning at 10:30 a.m. EDT on Wednesday, May 27, 2020. Stockholders will not be able to attend the Annual Meeting in person.

ShowHide Related Items >><<
ONTX Onconova
$0.33 /

+0.0075 (+2.35%)

11/26/19 Maxim
Onconova downgraded to Hold from Buy at Maxim
07/25/19
Fly Intel: Top five analyst initiations
07/25/19 Noble Capital
Onconova initiated with an Outperform at Noble Capital
Hot Stocks
Onconova appoints Terri Shoemaker to board of directors » 08:20
04/27/20
04/27
08:20
04/27/20
08:20
ONTX

Onconova

$0.30 /

+0.0001 (+0.03%)

, PDDPF

Medexus

$0.00 /

+ (+0.00%)

Onconova Therapeutics…

Onconova Therapeutics (ONTX) announced the nomination of biotech industry veteran Terri Shoemaker to the Company's Board of Directors. Ms. Shoemaker will join as a Director on Onconova's Board of Directors following election of the slate of directors at the annual general meeting of stockholders scheduled for May 27, 2020. Shoemaker has served as the President and CEO of commercial-stage specialty pharmaceutical company Medexus Pharma (PDDPF) since October 2018.

ShowHide Related Items >><<
ONTX Onconova
$0.30 /

+0.0001 (+0.03%)

11/26/19 Maxim
Onconova downgraded to Hold from Buy at Maxim
07/25/19
Fly Intel: Top five analyst initiations
07/25/19 Noble Capital
Onconova initiated with an Outperform at Noble Capital
PDDPF Medexus
$0.00 /

+ (+0.00%)

03/27/20 Canaccord
Medexus downgraded to Speculative Buy from Buy at Canaccord
Syndicate
Onconova files $150M mixed securities shelf  17:30
04/24/20
04/24
17:30
04/24/20
17:30
ONTX

Onconova

$0.30 /

+0.0001 (+0.03%)

 
ShowHide Related Items >><<
ONTX Onconova
$0.30 /

+0.0001 (+0.03%)

11/26/19 Maxim
Onconova downgraded to Hold from Buy at Maxim
07/25/19
Fly Intel: Top five analyst initiations
07/25/19 Noble Capital
Onconova initiated with an Outperform at Noble Capital
Over a quarter ago
Hot Stocks
Onconova announces completion of patient enrollment in INSPIRE trial » 16:14
03/24/20
03/24
16:14
03/24/20
16:14
ONTX

Onconova

$0.36 /

+0.052 (+16.67%)

"Following…

"Following significant progress throughout 2019, our team's immediate focus remains to advance our pivotal Phase 3 INSPIRE trial to the next milestone," said Steven Fruchtman, president and CEO. "We are excited to announce the completion of the planned enrollment of 360 patients in the INSPIRE trial in higher-risk (HR) MDS patients. INSPIRE represents one of the largest studies ever conducted in this patient population. Based on survival trends on the INSPIRE trial to date, we anticipate reporting topline survival data in the second half of 2020 and presenting the results at a medical meeting later this year. We continue to analyze deep genomic sequencing, including mutations of the Ras pathway, on these patients. Important genomic results were presented at ASH 2019 and additional data is expected to be presented at future medical meetings." Fruchtman continued, "We are also pleased about the progress of our plans for additional investigator-initiated studies - including the Phase 1/2a study of rigosertib plus nivolumab for the treatment of Stage IV KRAS mutated lung adenocarcinoma. We anticipate the first patient to be entered onto the trial once the COVID-19 environment improves sufficiently."

ShowHide Related Items >><<
ONTX Onconova
$0.36 /

+0.052 (+16.67%)

11/26/19 Maxim
Onconova downgraded to Hold from Buy at Maxim
07/25/19
Fly Intel: Top five analyst initiations
07/25/19 Noble Capital
Onconova initiated with an Outperform at Noble Capital
Hot Stocks
Onconova regains rigosertib rights in Greater China » 08:40
01/23/20
01/23
08:40
01/23/20
08:40
ONTX

Onconova

$0.37 /

-0.0405 (-9.88%)

Onconova Therapeutics…

Onconova Therapeutics announced that it has regained the rights to rigosertib in Greater China. Onconova regained the rights from HanX Biopharmaceuticals as a result of the termination of the Onconova-HanX License Agreement pursuant to its terms due to HanX failing to make required payments under the agreement. In exchange for transition assistance and upon further regulatory, development and commercial progress in Greater China, HanX may be eligible to receive from Onconova incentive milestones and royalty payments. The Greater China territory, including mainland China, Hong Kong, Macau and Taiwan, represents one of the key world pharmaceutical markets.

ShowHide Related Items >><<
ONTX Onconova
$0.37 /

-0.0405 (-9.88%)

11/26/19 Maxim
Onconova downgraded to Hold from Buy at Maxim
07/25/19
Fly Intel: Top five analyst initiations
07/25/19 Noble Capital
Onconova initiated with an Outperform at Noble Capital
Syndicate
Onconova announces $10M registered direct offering priced at-the-market » 11:34
12/31/19
12/31
11:34
12/31/19
11:34
ONTX

Onconova

$0.54 /

+0.106 (+24.65%)

Onconova Therapeutics…

Onconova Therapeutics announced that it has entered into definitive agreements with two healthcare-focused institutional investors for the issuance and sale in a registered direct offering of 27.66M shares of its common stock at a purchase price of 36.15c per share, for aggregate gross proceeds of approximately $10M in a registered direct offering priced at-the-market under Nasdaq rules. The company currently intends to use the net proceeds from the offering for working capital and general corporate purposes, including advancing preparations for a planned New Drug Application filing to the FDA for intravenous rigosertib in second-line higher-risk MDS in 2020, and advancing preparations for commercialization if the NDA is approved. The company surpassed 90% of the required enrollment of the INSPIRE Trial in November 2019 and anticipates reporting topline data in the first half of 2020, following full enrollment and reaching the number of required survival events. With the additional expected proceeds from the offering and the proceeds from recent warrant exercise, the company believes that it has the sufficient funds to extend operations and ongoing trials late into Q1 of 2021. The offering is expected to close on or about January 3, subject to the satisfaction of customary closing conditions. H.C. Wainwright is acting as the exclusive placement agent for the offering.

ShowHide Related Items >><<
ONTX Onconova
$0.54 /

+0.106 (+24.65%)

11/26/19 Maxim
Onconova downgraded to Hold from Buy at Maxim
07/25/19
Fly Intel: Top five analyst initiations
07/25/19 Noble Capital
Onconova initiated with an Outperform at Noble Capital

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.